Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother. 1992 Jun; 36(6):1280-3.